SIRT1 Inhibition Alleviates Gene Silencing in Fragile X Mental Retardation Syndrome

Section on Genomic Structure and Function, Laboratory of Molecular and Cellular Biology, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
PLoS Genetics (Impact Factor: 8.17). 03/2008; 4(3):e1000017. DOI: 10.1371/journal.pgen.1000017
Source: PubMed

ABSTRACT Author Summary
Fragile X syndrome is the leading cause of heritable intellectual disability. The affected gene, FMR1, encodes FMRP, a protein that regulates the synthesis of a number of important neuronal proteins. The causative mutation is an increase in the number of CGG•CCG-repeats found at the beginning of the FMR1 gene. Alleles with >200 repeats are silenced. The silencing process involves DNA methylation as well as modifications to the histone proteins around which the DNA is wrapped in vivo. Treatment with 5-azadeoxycytidine, a DNA methyltransferase inhibitor, reactivates the gene. However, this reagent is toxic and since no DNA demethylase has been found in humans, methylation inhibitors are not useful in cells like neurons that no longer divide. We show here that splitomicin is also able to reactivate the Fragile X allele. It does so by inhibiting a protein deacetylase, SIRT1, thus favoring the action of another enzyme, hMOF that reverses the SIRT1 modification. We also found that 5-azadeoxycytidine acts, at least in part, by reversing the effect of SIRT1. However, since splitomicin reactivation occurred without DNA demethylation, DNA replication is not necessary for its efficacy. Thus, unlike DNA methylation inhibitors, SIRT1 inhibitors may be able to reactivate Fragile X alleles in neurons.

Download full-text


Available from: Daman Kumari, Jul 08, 2015
  • Source
    • "Recently, the class III HDAC inhibitor nicotinamide (Ghosh and Feany, 2004) has been shown to increase frataxin expression and decrease H3K9me3 and H3K27me3 at the FXN gene in FRDA cells and mouse models and this compound is now in early stage clinical trials (Chan et al., 2013) (Table 2). Furthermore, other HDAC inhibitors such as sirtinol (Ota et al., 2006), splitomicin (Biacsi et al., 2008), LBH589 (Garbes et al., 2009), and oxamflatin (Kim et al., 1999) have shown positive effects in other "
    [Show abstract] [Hide abstract]
    ABSTRACT: Friedreich ataxia (FRDA) is a lethal autosomal recessive neurodegenerative disorder caused primarily by a homozygous GAA repeat expansion mutation within the first intron of the FXN gene, leading to inhibition of FXN transcription and thus reduced frataxin protein expression. Recent studies have shown that epigenetic marks, comprising chemical modifications of DNA and histones, are associated with FXN gene silencing. Such epigenetic marks can be reversed, making them suitable targets for epigenetic-based therapy. Furthermore, since FRDA is caused by insufficient, but functional, frataxin protein, epigenetic-based transcriptional re-activation of the FXN gene is an attractive therapeutic option. In this review we summarize our current understanding of the epigenetic basis of FXN gene silencing and we discuss current epigenetic-based FRDA therapeutic strategies.
    Frontiers in Genetics 06/2014; 5:165. DOI:10.3389/fgene.2014.00165
  • Source
    • "Mammalian HDACs are classified into two families: Sirt2 and HDACs (1–11, also known as Rpd3/Hda1). The latter is further grouped by functional similarity into four classes, class I (HDACs 1, 2, 3, and 8), II (HDACs 4, 5, 7, and 9), III (HDACs 6 and 10) and IV (HDAC 11; Thiagalingam et al., 2003; Ekwall, 2005; Biacsi et al., 2008; Yang and Seto, 2008). Class I HDACs are known to have critical functions in transcription repression and epigenetic landscaping during early murine development (Yang and Seto, 2008), and all members of which have been proven to be essential for mouse viability. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The neural crest (NC) is a multipotent, migratory cell population that arises from the developing dorsal neural fold of vertebrate embryos. Once their fates are specified, neural crest cells (NCCs) migrate along defined routes and differentiate into a variety of tissues, including bone and cartilage of the craniofacial skeleton, peripheral neurons, glia, pigment cells, endocrine cells, and mesenchymal precursor cells (Santagati and Rijli,2003; Dupin et al.,2006; Hall,2009). Abnormal development of NCCs causes a number of human diseases, including ear abnormalities (including deafness), heart anomalies, neuroblastomas, and mandibulofacial dysostosis (Hall,2009). For more than a century, NCCs have attracted the attention of geneticists and developmental biologists for their stem cell-like properties, including self-renewal and multipotent differentiation potential. However, we have only begun to understand the underlying mechanisms responsible for their formation and behavior. Recent studies have demonstrated that epigenetic regulation plays important roles in NC development. In this review, we focused on some of the most recent findings on chromatin-mediated mechanisms for vertebrate NCC development.
    Birth Defects Research Part A Clinical and Molecular Teratology 08/2011; 91(8):788-96. DOI:10.1002/bdra.20797 · 2.21 Impact Factor
  • Source
    • "The fragile X mental retardation gene FMR1 is known to associate with acetylated histone H3 and H4, with acetylation being reduced in fragile X cells. Histone hyperacetylating drugs such as 4-phenylbutyrate and TsA produce significant gene reactivation, indicating that histone acetylation , together with DNA demethylation, are the main epigenetic switches activating the expression of the FMR1 gene (Tabolacci et al. 2005; Biacsi et al. 2008). In addition, activity of the class I histone deacetylase HDAC3 has been shown to be regulated by dephosphorylation, which is brought about by protein phosphatase type-4, implicating this enzyme in the regulation of chromatin remodeling (Cohen et al. 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Injection of the histone deacetylase inhibitor trichostatin A (TsA) to rats has been shown to decrease their motivation to self-administer cocaine. In the present study, we investigated alterations in gene expression patterns in the anterior cingulate cortex and nucleus accumbens of rats self-administering cocaine and treated with TsA. Using oligonucleotide microarrays, we identified 722 probe sets in the cortex and 136 probe sets in the nucleus accumbens that were differentially expressed between vehicle and TsA-treated rats that self-administered cocaine. Microarray data were validated by real-time PCR for seven genes. Using immunohistochemistry, we further investigated the expression of Lis1 and reelin genes, because (i) they were similarly regulated by TsA at the mRNA level; (ii) they belong to the same signal transduction pathway; (iii) mutations within both genes cause lissencephaly. Cocaine self-injection was sufficient to activate the two genes at both the mRNA and protein levels. TsA treatment was found to up-regulate both Lis1 and reelin protein expression in the cortex and to down-regulate it in the nucleus accumbens of rats self-administering cocaine. The data suggest that the two proteins contribute to establish neurobiological mechanisms underlying brain plasticity whereby TsA lowers the motivation for cocaine.
    Journal of Neurochemistry 04/2010; 113(1):236-47. DOI:10.1111/j.1471-4159.2010.06591.x · 4.24 Impact Factor